Variation in Endpoints for FDA Approved Migraine Therapies

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A Dreamy Journey with a Dragon 56 min · 23 Sep 2026 · Get Sleepy: stories for sleep

Australia joins Europe? 57 min · 23 Sep 2026 · The Bugle

Should Ireland share its corporation tax bonanza with the EU? 27 min · 23 Sep 2026 · Inside Business with Ciaran Hancock

Will Piers Morgan make Earl Spencer pulp his own book? 34 min · 23 Sep 2026 · The News Agents

NPR News: 09-23-2026 10AM EDT 4 min · 23 Sep 2026 · NPR News Now

Trump Melts Down On Reporter; Insane AI Rebrand? Historic Polling Has MAGA In Crisis 18 min · 23 Sep 2026 · IHIP News

Report any issue

Source

Recorded07 Sep 2023

Publisherneurology.libsyn.com ↗

Handlerec:5447544

Show notes

Dr. Jessica Ailani talks with Dr. Aaron Kesselheim and Leigh Sharpless about the endpoints used in trials supporting the US FDA approval of medications treating migraines. Read the related article in Neurology. This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in